Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor–associated arthralgias in early-stage breast cancer …

NL Henry, JM Unger, AF Schott… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …
被引用次数：102 相关文章
[HTML] nih.gov

[HTML][HTML] Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage …

NL Henry, JM Unger, AF Schott… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer …

NL Henry, JM Unger, AF Schott… - Journal of Clinical …, 2018 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Adherence to aromatase inhibitor (AI)
therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms …

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer …

NL Henry, JM Unger, AF Schott… - Journal of Clinical …, 2017 - europepmc.org
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …

Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer …

NL Henry, JM Unger, AF Schott… - Journal of …, 2018 - mdanderson.elsevierpure.com
Purpose: Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer …

NL Henry, JM Unger, AF Schott… - Journal of clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …

Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer …

NL Henry, JM Unger, AF Schott… - Journal of Clinical …, 2018 - scholars.northwestern.edu
Purpose: Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …
[HTML] nih.gov

[HTML][HTML] Randomized Multicenter Placebo-Controlled Clinical Trial of Duloxetine versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early Stage Breast …

NL Henry, JM Unger, AF Schott… - Journal of clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Adherence to aromatase inhibitor (AI) therapy for early stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is FDA-approved …

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer …

NL Henry, JM Unger, AF Schott… - Journal of Clinical …, 2017 - europepmc.org
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is
limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and …